Physician profile
Ryan M Griffith
NPI 1265876163
$3,328.56
in general payments reported to CMS, 2019-2025
32 companies · $587 in 2025
The $587 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $25.29 · 2021: $419 · 2022: $498 · 2023: $1,141 · 2024: $465 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,093 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,093.25 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $394.89 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| United Therapeutics Corporation | $340.11 | 2020-2025 | Tyvaso, Remodulin, Tyvaso |
| Astrazeneca Pharmaceuticals LP | $336.14 | 2019-2025 | Breztri, Tezspire, Fasenra |
| Genzyme Corporation | $309.76 | 2021-2025 | |
| Baxter Healthcare | $229.94 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Insmed, INC. | $180.19 | 2019-2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.73 | 2021-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Sanofi-Aventis U.S. LLC | $158.98 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $141.94 | 2022-2024 | Glassia |
| Mylan Specialty L.P. | $124.33 | 2022-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $109.42 | 2021-2025 | Dupixent |
| Genentech USA, INC. | $95.32 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $93.76 | 2021-2022 | |
| Axsome Therapeutics, INC. | $84.65 | 2023 | Sunosi |
| Grifols USA, LLC | $70.45 | 2023-2025 | Prolastin-C Liquid |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $59.66 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $54.60 | 2025 | Gemtesa |
| Amgen INC. | $46.46 | 2022-2024 | Tezspire |
| Inogen, INC. | $37.42 | 2023-2024 | Inogen |
| Inspire Medical Systems, INC. | $34.73 | 2023-2025 | Inspire |
| Philips North America LLC | $33.69 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $31.88 | 2021 | |
| Harmony Biosciences LLC | $26.79 | 2024 | |
| Merck Sharp & Dohme LLC | $21.44 | 2025 | Winrevair |
| Advanced Respiratory, INC | $20.93 | 2021 | |
| Electromed, INC. | $19.19 | 2023 | Smartvest |
| La Jolla Pharmaceutical Company | $19.09 | 2024 | Giapreza |
| Bayer Healthcare Pharmaceuticals INC. | $17.07 | 2021 | |
| Viatris Specialty LLC | $16.95 | 2025 | Yupelri |
| Cordis US Corp. | $15.96 | 2025 | Mynx Control Venous |
| Idorsia Pharmaceuticals US INC | $14.69 | 2023 | Quviviq |
| Pulmonx Corporation | $14.40 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.